Since December 2021, the Dutch guidelines have recommended tocilizumab as the first-choice drug for the treatment of COVID-19-positive pregnant women if they qualify for anti-IL-6 therapy; the indication and dosage of tocilizumab should ideally be determined by a multidisciplinary team including at least a pulmonologist and/or internist and/or intensivist and a perinatologist [54]. This evidence concerns the gene IL6 and COVID-19.